Comparing the quality of life of neuropathic patients treated with gabapentin and pregabalin at the neuropathic poly of the NTB provincial hospital in 2019

被引:1
作者
Qiyaam, Nurul [1 ]
Nopitasari, Baiq Leny [1 ]
Muhajiji, Haerul [2 ]
机构
[1] Univ Muhammadiyah Mataram, Fac Hlth Sci, Dept Pharmacol & Clin Pharm, Mataram 83127, Indonesia
[2] Univ Muhammadiyah Mataram, Fac Hlth Sci, Dept Pharm, Mataram, Indonesia
来源
PHARMACY EDUCATION | 2021年 / 21卷 / 02期
关键词
EQ-5D-3L; EQ-VAS; Gabapentin; Neuropathic pain; Pregabalin; Quality of life; PAIN;
D O I
10.46542/pe.2021.212.225229
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Introduction: Neuropathic pain is caused by the malfunctioning of the central nervous system or the peripheral nervous system. This pain is chronic and so it disrupts a patient's quality of life which can lead to them becoming frustrated. Aim: The purpose of this study was to compare the quality of life of neuropathic patients using either gabapentin or pregabalin at the neuropathic clinic of the Regional General Hospital of West Nusa Tenggara Province in 2019. Methods: This study used a cross-sectional study design. The sampling technique that was used was purposive sampling which was carried out by filling out the EQ-5D-3L and EQ-VAS questionnaires. Results: The results showed no significant difference between the quality of life of the patients using gabapentin and the patients using pregabalin as the EQ-5D-3L questionnaire had a value of p = 0.683. There was no significant difference between the quality of life between the gabapentin and pregabalin groups using the EQ-VAS questionnaire which had a value of p = 1.000.
引用
收藏
页码:225 / 229
页数:5
相关论文
共 16 条
  • [1] Annisa W. R., PENILAIAN KUALITAS H, P2
  • [2] [Anonymous], 2012, HORIZANT MONOGRAPH, P15
  • [3] Consensus guidelines: Treatment planning and options
    Argoff, CE
    Backonja, MM
    Belgrade, MJ
    Bennett, GJ
    Clark, MR
    Cole, BE
    Fishbain, DA
    Irving, GA
    McCarberg, BH
    McLean, MJ
    [J]. MAYO CLINIC PROCEEDINGS, 2006, 81 (04) : S12 - S25
  • [4] Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial
    Backonja, M
    Beydoun, A
    Edwards, KR
    Schwartz, SL
    Fonseca, V
    Hes, M
    LaMoreaux, L
    Garofalo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21): : 1831 - 1836
  • [5] Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain
    Boyle, Julia
    Eriksson, Malin E. V.
    Gribble, Laura
    Gouni, Ravi
    Johnsen, Sigurd
    Coppini, David V.
    Kerr, David
    [J]. DIABETES CARE, 2012, 35 (12) : 2451 - 2458
  • [6] Centre for Clinical Practice at NICE (UK), 2013, NEUROPATHIC PAIN PHA
  • [7] Trigeminal neuralgia New classification and diagnostic grading for practice and research
    Cruccu, Giorgio
    Finnerup, Nanna B.
    Jensen, Troels S.
    Scholz, Joachim
    Sindou, Marc
    Svensson, Peter
    Treede, Rolf-Detlef
    Zakrzewska, Joanna M.
    Nurmikko, Turo
    [J]. NEUROLOGY, 2016, 87 (02) : 220 - 228
  • [8] Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis
    Davari, Majid
    Amani, Bahman
    Amani, Behnam
    Khanijahani, Ahmad
    Akbarzadeh, Arash
    Shabestan, Rouhollah
    [J]. KOREAN JOURNAL OF PAIN, 2020, 33 (01) : 3 - 12
  • [9] Chronic neuropathic pain - Mechanisms, diagnosis, and treatment
    Harden, RN
    [J]. NEUROLOGIST, 2005, 11 (02) : 111 - 122
  • [10] Hutapea F. S., 2016, E CLIN, V4, DOI [10.35790/ecl.4.1.2016.12115, DOI 10.35790/ECL.4.1.2016.12115]